Effects of Chromium Supplementation on Parameters of the Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus
NCT ID: NCT00145093
Last Updated: 2005-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
60 participants
INTERVENTIONAL
2004-08-31
2005-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients meeting the inclusion and not the exclusion criteria will be sent a letter containing information about the study and that they will be called within 2 weeks by one of the investigators. If the patient agrees to come for a fist visit he or she will be invited for a first visit to come to the general practice of Heerde.
Informed Consent:
During the telephone call and the first visit, patients will be able to ask any question. When the patient is properly informed and gives written informed consent the patient will be included for this study. Specific items such as duration of the study, the frequency of follow-up visits, and the voluntary nature of participation will be discussed prior to obtaining informed consent. Also, because of potential reproductive toxicity (no reports are known of developmental toxicity studies on Cr3+ compounds given orally), we will advice patients to take contraceptive precautions (33).
Stop criteria:
When a patient has any possible drug intolerance the patient will be asked to contact us. We will note every possible side effect. If there is any serious side effect the patient will be asked to stop with the intervention medication.
Power and Sample Size Calculations:
Sample size was calculated by using the computer program G-power. Mean HbA1c of patients with HbA1c 7-8,5% in a general practise in our region is 7,70% (SD 0,44). Powered to detect a 0,5% absolute reduction in HbA1c in the six-month follow-up of patients treated with chromium as compared to placebo patients. With a power 95%, alpha 0.05 2-tailed, the total sample size is 44 (22 in the first group and 22 in the second group).
Randomisation:
60 patients who will meet the inclusion criteria are randomly assigned in a double-blind trial to receive treatment A or B in addition to their current therapy for six months. Method of blinding randomisation: drug packages are labelled with the randomisation code by the hospital pharmacy. Neither the physician nor the patient will be informed of the treatment. There is no delay between study enrolment and randomisation.
Intervention:
Two treatment protocols are proposed. Treatment A consist of 400 microgram Bio-chromium/day and treatment B consists of a placebo. One type of chromium tablets will be made; 100 microgram Cr/tablet. Placebo is made to appear identical with the chromium tablets. Patients are instructed to ingest 2 tablets of the study drug with breakfast and 2 with diner.
Measures:
Medical history consists of duration of diabetes, diabetes medication, general medication, renal or hepatic diseases and recent complaints. Body fat percentages will be measured using the OMRON BF306 (HBF-306-E). Patients are weighed while wearing clothes on bare feet. Length is measured while standing on bare feet and blood pressure measured when the patient is in a sitting position according to the Dutch College of General Practitioners (34).
Serum creatinine, hepatic enzyme (PT), HbA1c, Haemoglobin (Hb), fasting glucose, fasting insulin, serum total cholesterol, LDL, HDL, and triglycerides will be measured at baseline with the standard procedure in our hospital (Weezenlanden Location, Isala Clinics).
At baseline and after six months, also serum chromium will be measured. Extra citrate and serum collection tubes will be frozen for additional measurements, when needed. Also 24-h urine will be collected at baseline and after 6 months and volume, creatinine, protein and albumin will be measured. Three tubes containing both 2 cc of urine will be frozen for additional measurements. These (extra) analyses will only be made after given information and approval of the patient, and after approval of the medical ethical committee.
Follow up:
At baseline, an appointment will be made for the following visit and an appointment for a telephone call after 4 weeks. During this call, patients will be asked if they had any complaint which started after inclusion to this study. For stimulating compliance, patients will be asked how they use their tablets. When this is different from described in this protocol, patients will be advised accordingly. Furthermore, patients will be able to ask any question during this telephone call.
Patients can call us when there is any possible adverse or toxic effects of the drug during office hours.
After 3 months, only HbA1c and Hb will be measured. The other measures as described above, except for length will be measured at baseline and after 6 months.
Handling of losses to follow-up:
Patients withdrawn from study medication will receive regular follow-up until the end of the 6-month follow-up period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Baker's yeast (Bio Chromium)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treated with oral blood glucose lowering therapy, which has not been changed for the last three months.
Exclusion Criteria
* patients with a serum creatinine concentration over 150 micromol/l in men and 120 micromol/l in women, Cockcroft \< 50 ml/min
* hepatic enzyme levels (ALAT) over 90 U/l (2 x upper limit)
* patients known with allergy or intolerance for yeast
* patients currently taking chromium supplements
* patients treated with insulin.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pharma Nord
INDUSTRY
Medical Research Foundation, The Netherlands
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Henk JG Bilo, MD PhD FRCP
Role: PRINCIPAL_INVESTIGATOR
Isala clinics, medical research foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
General Practice
Heerde, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04.0536P
Identifier Type: -
Identifier Source: org_study_id